Paper39397484
Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.
Moakes CA and 14 others. Health Technol Assess, 2024. Cited by 7 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT. Papers, record 39397484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39397484
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.
- PubMed
- Publication types
- Journal Article, Multicenter Study, Randomized Controlled Trial, Clinical Trial, Phase III, Pragmatic Clinical Trial, Equivalence Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cost-Benefit Analysis | Major topic |
| Endovascular Procedures | Major topic |
| Amputation, Surgical | Major topic |
| Quality-Adjusted Life Years | Major topic |
| Chronic Limb-Threatening Ischemia | Major topic |
| Humans | |
| Male | |
| Female | |
| Aged | |
| Popliteal Artery | |
| Peripheral Arterial Disease | |
| Middle Aged | |
| Quality of Life | |
| United Kingdom | |
| Technology Assessment, Biomedical | |
| Limb Salvage | |
| Ischemia |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34,481,898 | Procedural and 12-month in-hospital costs of primary infra-popliteal bypass surgery, infrapopliteal best endovascular treatment, and major lower limb amputation for chronic limb threatening ischemia. | J Vasc Surg | 2022 | https://conductscience.org/library/papers/34481898 | PubMed |
| 2 | 35,680,042 | Prediction Models for Two Year Overall Survival and Amputation Free Survival After Revascularisation for Chronic Limb Threatening Ischaemia. | Eur J Vasc Endovasc Surg | 2022 | https://conductscience.org/library/papers/35680042 | PubMed |
| 3 | 26,739,146 | Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. | Trials | 2016 | https://conductscience.org/library/papers/26739146 | PubMed |
| 4 | 21,479,777 | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). | Qual Life Res | 2011 | https://conductscience.org/library/papers/21479777 | PubMed |
| 5 | 9,794,854 | Analysis and interpretation of cost data in randomised controlled trials: review of published studies. | BMJ | 1998 | https://conductscience.org/library/papers/9794854 | PubMed |
| 6 | 28,602,580 | A Comparison of Outcomes in Patients with Infrapopliteal Disease Randomised to Vein Bypass or Plain Balloon Angioplasty in the Bypass vs. Angioplasty in Severe Ischaemia of the Leg (BASIL) Trial. | Eur J Vasc Endovasc Surg | 2017 | https://conductscience.org/library/papers/28602580 | PubMed |
| 7 | 15,150,820 | Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. | Diabetes Metab Res Rev | 2004 | https://conductscience.org/library/papers/15150820 | PubMed |
| 8 | 33,527,304 | The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data. | Appl Health Econ Health Policy | 2021 | https://conductscience.org/library/papers/33527304 | PubMed |
| 9 | 29,599,067 | Editor's Choice - A Comparison of Clinical Outcomes Between Primary Bypass and Secondary Bypass After Failed Plain Balloon Angioplasty in the Bypass versus Angioplasty for Severe Ischaemia of the Limb (BASIL) Trial. | Eur J Vasc Endovasc Surg | 2018 | https://conductscience.org/library/papers/29599067 | PubMed |
| 10 | 28,102,550 | Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. | Stat Med | 2017 | https://conductscience.org/library/papers/28102550 | PubMed |
| 11 | 21,963,765 | 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | J Am Coll Cardiol | 2011 | https://conductscience.org/library/papers/21963765 | PubMed |
| 12 | 16,900,281 | The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. | Qual Life Res | 2006 | https://conductscience.org/library/papers/16900281 | PubMed |
| 13 | 7,827,647 | Costs, effects and C/E-ratios alongside a clinical trial. | Health Econ | 1994 | https://conductscience.org/library/papers/7827647 | PubMed |
| 14 | 2,115,096 | The CE plane: a graphic representation of cost-effectiveness. | Med Decis Making | 1990 | https://conductscience.org/library/papers/2115096 | PubMed |
| 15 | 20,307,380 | Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. | Health Technol Assess | 2010 | https://conductscience.org/library/papers/20307380 | PubMed |
| 16 | 20,435,260 | Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification. | J Vasc Surg | 2010 | https://conductscience.org/library/papers/20435260 | PubMed |
| 17 | 31,230,866 | Editor's Choice - The Prognostic Value of the WIfI Classification in Patients with Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-Analysis. | Eur J Vasc Endovasc Surg | 2019 | https://conductscience.org/library/papers/31230866 | PubMed |
| 18 | 37,116,524 | A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37116524 | PubMed |
| 19 | 31,303,293 | Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. | Lancet Glob Health | 2019 | https://conductscience.org/library/papers/31303293 | PubMed |
| 20 | 36,342,173 | Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36342173 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,920,533 | Sitting Baduanjin-based rehabilitation programme following endovascular therapy in patients with chronic limb-threatening ischemia: protocol for a WeChat mini program-assisted multicentre randomized controlled trial. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42920533 | PubMed |
| 42,550,504 | Cost-Effectiveness of Endovascular vs Open Surgery for Chronic Limb-Threatening Ischemia. | JAMA Netw Open | 2026 | https://conductscience.org/library/papers/42550504 | PubMed |
| 42,196,923 | From Angiosome to Woundosome: An Interdisciplinary Approach to Personalized Revascularization in Chronic Limb-Threatening Ischemia. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42196923 | PubMed |
| 40,564,084 | Preliminary Evaluation of 3D-Printed Alginate/Gelatin Scaffolds for Protein Fast Release as Suitable Devices for Personalized Medicine. | Biomedicines | 2025 | https://conductscience.org/library/papers/40564084 | PubMed |
| 40,097,243 | Algorithm for the Revascularization of Infrainguinal Arterial Disease. | Vasc Specialist Int | 2025 | https://conductscience.org/library/papers/40097243 | PubMed |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| ISRCTN | ISRCTN27728689 |
Source ISRCTN
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39397484
GET https://conductscience.org/api/papers/v1/39397484/references?page=2